REG - Intuitive Invests.Gp - Investment in Yourgene Health plc

Intuitive InvestmentsAnnouncement

22/02/2021 07:00

RNS Number : 8129P
  
Intuitive Investments Group plc
  
22 February 2021
  
 

Intuitive Investments Group plc
 
Investment in Yourgene Health plc
 
Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £248,765 to acquire 1,584,920 ordinary shares of Yourgene Health plc (AIM: YGEN) ("Yourgene") at an average price of 15.70 pence per share (the "Investment"). 
 
Yourgene is an international molecular diagnostics group which develops and commercialises genetic products and services. Yourgene works in partnership with global leaders in DNA technology to advance diagnostic science. 
 
Robert Naylor, CEO of IIG, has an investment predating IIG's investment, of 164,456 ordinary shares in Yourgene. Accordingly, Robert Naylor did not vote as a member of the investment team of IIG in approving the Investment.
 
The Investment in Yourgene is the Company's sixth investment following its IPO in mid-December 2020.
 
For further information, please contact:
 



Intuitive Investments Group plc


www.iigplc.com




David Evans, Executive Chairman
Robert Naylor, CEO


Via Walbrook PR




 


 




Strand Hanson Limited - Nominated Adviser


+44 (0) 20 7409 3494




James Harris / James Dance / James Bellman
 


 
 
























Turner Pope Investments (TPI) Ltd - Broker


+44 (0) 20 3657 0050




Andrew Thacker / Zoe Alexander


 




 


 




Walbrook PR Limited - Media & Investor Relations


+44 (0)20 7933 8780 or intuitive@walbrookpr.com




Sam Allen / Paul McManus


+44 (0)7748 651 727 / +44 (0) 7980 541 893



 
About Intuitive Investments Group plc (www.iigplc.com)
The Company is a newly established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders.
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
MSCSELESFEFSEIE